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Available online 18 April 2016Despite advances in revascularization techniques, acute myocardial infarction (AMI) still carries signiﬁcant
morbidity and mortality. Over the past decade, the use of regenerative medicine methodologies, and speciﬁcally
bonemarrow derived progenitor cell therapy has been tested inmore than 35 Phase I and Phase II clinical studies
demonstrating overall safety and measurable clinical beneﬁt, 12–61 months post-treatment as evaluated by
improvement in the Left Ventricular Ejection Fraction (LVEF) and changes in infarct size post AMI. Recent
meta-analysis on the subject highlighted several important parameters that include timing of the cell therapy
post AMI, the cell dose, and the baseline LVEF on enrollment. We further postulate that the mythologies and
timing for cell handling and delivery including the speciﬁc devices are essential for clinical efﬁcacy. Addressing
this we have developed a rapid 60 to 90 minute process and integrated system which is carried out in the
heart catheter lab, using a combination product (U.S. Food and Drug broadly deﬁned as the combination of
co-labeled optimized “cell friendly” devices, effective cell/biological formulation and dose) for harvesting, pro-
cessing, verifying, and delivering an autologous dose of bonemarrow progenitor/stem cells via the intracoronary
artery proximal to the infarctmyocardial region. Themethodology has been demonstrated to be safe and feasible
for autologous in vivo use and presented by our groups' earlier studies1–3 and most recently used in a Phase Ib
critical limb ischemia trial of 17 subjects (NCT01472289) (manuscript under preparation). This is the ﬁrst case
study prior to beginning the AMIRST trial [Acute Myocardial Infarction Rapid Stem cell Therapy], speciﬁc to
our proprietary combination product kit for acutemyocardial infarction, and was completed under the Indepen-
dent Ethics Committee and Institutional Committee for StemCell Research and Therapy approval (TIEC/2011/32/
02) for process and safety endpoints post-treatment.
© 2016 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cell therapy is being widely explored in the management of various
unmet medical need, and our own group has demonstrated safety andfor Cellular Medicine (Cesca
ec 44, Gurgaon-122002, Delhi
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y. Production and hosting by Elsevierefﬁcacy of autologous bone marrow derived stem cells in treating vari-
ous clinical indications.1-3 Cardiovascular disease (CVD) is the number
one cause of morbidity and mortality worldwide. An estimated 17.3
million people died from CVDs in 2008, representing 30% of all global
deaths.4 Of these deaths, an estimated 7.3 million were due to coronary
heart disease and 6.2 million were due to stroke.5 More remarkably,
low- and middle-income countries are disproportionally affected, driv-
ing the need for regenerative therapies in lieu of chronic drug treatment
regimens. Regenerative therapies must be offered in formats eliminat-
ing the need for high cost GMP laboratory infrastructure or extensive
multi-hour usage of vascular catheter labs. Over 80% of CVD deaths
take place in low- and middle-income countries and occur almost
equally in men and women.4 In the progression of CVDs, plaque lesions
develop in arteries that result in the narrowing of vessels, and in severeB.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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vital parts of the heart. Such ischemia may be reversed if treated within a
short period of time by reperfusion therapy, and further prevention of
devastating remodeling is hypothesized by the infusion of adult tissue-
derived stem/progenitor cells. Despite signiﬁcant advances in medical
therapy and revascularization strategies, the prognosis of certain patients
with acutemyocardial infarction (AMI) remains dismalwithout the intro-
duction of early biological repair intervention.
Along with reperfusion, adjuvant progenitor cell therapy has been
shown to be potentially efﬁcacious in the repair and regeneration of
damaged heart tissue. These potent progenitor cells can be isolated
from different sources within the adult human body. Speciﬁcally, the
current cardiac regenerative ﬁeld is experiencing diverse adult stem/
progenitor cell clinical trials at different stages of clinical development
including bonemarrow derived mononuclear cells (BMMNCs),6–8 mes-
enchymal stem cells (MSCs),9 adipose tissue-derived stem cells,10 and
cardiac-derived expanded stem cells.11 Of the abovementioned cellular
populations, bone marrow derived mononuclear cells have received
greater scientiﬁc and translational attention. MSCs, although easily
expanded in a laboratory setting and creating the ideal off-the-shelf
cellular product, can generate local immune responses and disturb ho-
meostasis within a tissue environment by releasing inﬂammatory
mediators.12 Autologous bone marrow derived stem cell (aBMMNCs)
therapy has emerged as a novel approach to treat patients with residual
left ventricular dysfunction following AMI despite successful
revascularization.7,38 Autologous sources are preferable because immu-
nologic rejection is avoided by default.39 Theﬁrst clinical trial evaluating
the effects of stem cell therapy on ischemic heart failurewas reported in
2002. In 2006, three large randomized clinical trials (ASTAMI, REPAIR-
AMI, and TOPCARE-CHD) were published.40–42 Although results on the
beneﬁcial effects of stem cells on myocardial function from these ﬁrst
trials were somewhat conﬂicting, further clinical trials (BOOST, STAR-
HEART, SCIPIO, CADUCEUS, REGENT, FocusHF, and others) suggest
the beneﬁcial effects of stem cells on the function and remodeling of
ischemic myocardium.43–47 Autologous BMMNCs not only circumvent
the ethical and legal issues related to embryonic stem cells, but also
overcome the risk of transmitting diseases and immune rejection. In
last 12 years, autologous BMMNCs has been extensively studied for
cardiac repair and regeneration in a number of randomized-controlled
trials (RCTs). More than 1800 subjects have been investigated in these
studies, and there is a clear evidence for safety of this therapy, however,
its efﬁcacy is still debated because of inconsistent results reported in the
literature.27 Here we are presenting a case report utilizing our integrat-
ed treatment platform (combination product) that is speciﬁc for Acute
Myocardial Infarction and has appropriately considered the essential
devices, diagnostics, cell formulations, and instructions for use ensuring
the treatment meets the objectives of providing a safe, effective,
rapid, bedside therapy for treating low ejection fraction primary acute
myocardial infarction.
Case report
Case presentation
A 43 year old male, non-diabetic, normotensive, non-obese, smoker
presented with a history of two hours of chest pain and symptomatic of
an AMI into the emergency department. On admission, the patient
presented with a 2 mm ST segment elevation in V1 and V2 anterior
leads with on-going chest pains, and AMI was further conﬁrmed with
biochemical blood tests. The patient's Left Ventricular Ejection Fraction
(LVEF), was estimated to be around 35% by bedside 2D ECHO. Diagnostic
coronary angiography showed 95% occlusion in the LAD in the proximal
segment, and no collaterals were noted. RCA, and circumﬂex arteries
were patent. Primary percutaneous coronary intervention (PCI) was
performed within 24 h of onset of chest pains using a routine technique,
and a single drug-eluting stent was deployed in the proximal LAD withTIMI-3 grade ﬂow results. Post-PCI, the patient's LVEF remained b40%
at the 120 h time-point as measured by multigated acquisition (MuGA)
and ECHO, which met our inclusion criteria and is predictive of a higher
than acceptable one year mortality rate. Also, the ECG showed T-wave
inversion in anterior leads and resolution of J-point elevation post-PCI.
The patient was advised that he met the inclusion criteria for the
AMIRST clinical trial program using his own (autologous) bonemarrow
progenitor cells. The clinical trial is registered with clinicaltrials.gov
(NCT01536106) and is approved by the Institutional Ethics Committee
(IEC) (IEC Approval #TIEC/2011/32/02) and Institutional Committee
for Stem Cell Research (ICSCRT). The Patient, Primary Investigator and
Clinical Investigator concurred, and consent was obtained. On the
sixth day post PTCA/stent implant, the patient was transferred to the
heart catheterization laboratory, and the AMIRST (AcuteMyocardial In-
farction Rapid Stem cell Therapy) protocol was completed. The entire
procedure was completed within 90 min, in the catheterization labora-
tory using our point-of-care technology. As a preliminary safety study
prior to full subject enrollment, the patient was followed up for
24-months, and evaluated with standard diagnostic metrics. No major
adverse cardiac events (MACE) including re-hospitalization were
reported during the 24month follow-up period, demonstrating the pre-
liminary safety of the device output, that is, autologous bone marrow
cell concentrate enriched progenitor cells and the corresponding
adjuvant treatment. The patients' LVEF improved from 35% (Day
0) at the time of the AMIRST treatment to 60.3% following 24 months
post-AMIRST intervention. It is noted that although the authors believe
cardiac MRI is now the gold standard for measuring LVEF; in this study
we used MuGA as the enrollment measurement technique. Caution
should be taken in comparing MuGA and MRI LVEF results; however
the enrollment LVEF was conﬁrmed via a secondary method i.e. ECHO
and the 3-month and 24-months LVEF results were conﬁrmed by the
same radiology team.
Method: BMCePC adjuvant therapy
Upon written informed consent, and within our maximum window
of 10 days post MI, the patient was taken to the heart catheterization
laboratory (operating room suite) on Day 6 post-PCI; mildly to moder-
ately sedated using 0.2mcg/kg of Fentanyl, and 120mL of bonemarrow
was aspirated from the patient's iliac crest using an 11-gauge Jamshidi
needle optimized for cell harvest. Careful bonemarrow aspiration tech-
nique was employed to reduce peripheral blood contamination in the
aspirate. Following the aspiration, the bone marrow was processed
employing our proprietary point-of-care technology platform to pro-
duce bone marrow concentrate enriched in progenitor cells (BMCePC).
Our point-of-care technology processes autologous bone marrow to a
pre-determined multi-phasic concentrate effectively and safely in
minimal time ex-vivo within 90 min (from aspiration to delivery) in
the operating room. The technology employs a linked two phase strati-
ﬁcation process using optical sensors to detect the different cell strata
and additional sensors to detect the mass and volume. The point-of-
care device automatically separates the different cellular fractions into
their designated compartments. Our point-of-care technology is a
completely closed sterile system with minimal manipulation of the
cells, that is, no addition of xenogeneic or chemical substance at any
step from harvest to delivery (except anticoagulant) achieving at least
85% of cell yield. Rapid point-of-care quality testing instruments have
been optimized and are used to ensure a safe and consistent cell dose.
The cellular product obtained after processing the bone marrow using
our device contained a total of 3.54 × 108 BMMNCs. A guide-wire was
introduced into the femoral artery followed by a double lumen ultra-
low proﬁle PTA intracoronary catheter, and the patient had four sepa-
rate induced ischemia/progenitor cell infusions using the “stop-ﬂow”
technique before the entire optimal dose of nucleated cells was distally
delivered to the stent in the LAD. The complete process was accom-
plished in 90 min at patient's bedside. The patient's hematological and
Table 1
Clinical laboratory values pre- and post-BMCePC therapy.
Pre-BMCePC
infusion
Post-BMCePC
infusion
Day−2 Day 0
Hemoglobin (g/dL) 13.5 13.8
RBC count (×106/μL) 4.84 4.92
Platelet count (×103/mL) 110 120
Creatinine, serum (mg/dL) 0.8 0.9
Urea nitrogen (mg/dL) 13 12
Creatine kinase, serum 106 188
N-terminal pro-B type natriuretic peptide (pg/mL) 731.3 —
79V. Sanghi et al. / International Journal of the Cardiovascular Academy 2 (2016) 77–83biochemical parameters are listed in Table 1. There were no adverse
events (AE) or serious adverse events (SAE) reported during the proce-
dure. The patient remained hospitalized for telemetry an additional
24 hours post cell transplant, and released with standard cardiac
therapeutics as listed in Table 2.
Patient follow-up
The patient was scheduled for follow-up on 1, 2, 3, 6, 12 and
24 months to assess the primary endpoints of safety and the secondary
endpoints of efﬁcacy that include LVEF, MACE, cardiac remodeling and
quality of life assessments. The 12-month follow-up could not be
completed due to non-availability of patient, but all other follow-up
points were completed. No Major Adverse Cardiac Events (MACE) or
re-hospitalization events were reported. The patient continued to
follow a normal life, after 2 weeks post the AMIRST procedure. At the
1-month follow-up, HOLTER monitoring was performed for 23 h and
6 min. No ventricular ectopic were observed, and the heart variability
was normal. The slowest episode of bradycardia (HR 53 bpm, 1 min
13 s) was observed at midnight and the fastest episode of tachycardia
(HR 141bpm, 1min 2 s)was observed in the afternoon. Cardiac imaging
was performed at each follow-up. The cardiac chambers appeared
normal with no signs of pericardial effusion.
Overall, the study demonstrated preliminary safety of our bonemar-
row aspiration, processing and infusion methodology in an acute low
LVEF infarct patient post PTCA. Fig. 1 shows cardiacMR images obtained
3 and 24-months post-BMC infusion. At the 24-month follow-up, the
cardiacMR ﬁndingswere summarized as “Basal andmid-cavity anterior
and anteroseptal and apical anterior and septal and apex myocardial
post contrast sub-endocardial b25% to 50% with a focal spec of 75%
transmural hyper enhancement, consistent with ischemic infarction.”
The pre-BMC infusion cardiac MR imaging was performed on a
different instrument than the 3- and 24-months post-BMC infusion.
Therefore, an absolute quantitative equivalency measurement of LVEF
between the pre-treatment and 3-months post-treatment was evaluat-
ed cautiously. Also, the MuGA and ECHO scan results have a level of
user-dependency, and each result was cautiously interpreted.13,14 Nev-
ertheless, a considerable improvement in the LVEF has been noted over
the study period and between 3-months and 24-months follow-up,
post-BMC infusion, the LVEF further improved from 55.4% to 60.3% as
shown in Table 3. This degree of improvement is considered atypical
for a patient having suffered an ST elevated myocardial infarction with
an ejection fraction below 40% post reperfusion (stenting). The cardiac
output (volumetric) also showed an improvement from 2.7 L/min toTable 2
Medications prescribed on discharge post-BMCePC therapy.
Drug Dose Frequency Drug class
Aspirin 150 mg Oral, once daily Anti-platelet
Copidogrel 75 mg Oral, twice daily Anti-platelet
Rosuvastatin 20 mg Oral, once daily Statin
Pantoprazole 40 mg Oral, once daily Dyspepsia/Antacid3.4 L/min over the same period, and is a secondary endpoint. No reduc-
tion in scar size was observed with a heart mass of 115.5 g and a scar
mass of 11.5 g (approximately 11%).
Discussion
The AMIRST trial has been designed to determine the safety and
preliminary effectiveness of our patented point-of-care technology
(combination product) for aspiration, processing and intracoronary
administration of BMCePCs for treatment of acute ST segment elevation
MI with low ejection fraction. Here we are presenting the preliminary
safety and effectiveness data from a single case prior to starting an
elaborate, randomized-controlled AMIRST trial on a larger patient pop-
ulation. The results from this case study demonstrate that our combina-
tion product which is the ﬁrst of its kind point-of-care technology that
includes all the devices necessary for aspiration, processing and delivery
of BMCePCs and also, checks the quality and quantity of the cells prior to
administration using our optimized point-of-care diagnostic devices is
efﬁcacious for cardiac disorders in terms of safety and feasibility. We
observed no signiﬁcant major adverse effects in terms of MACE or
pro-arrhythmia following administration of BMCePCs, and there was
signiﬁcant improvement in myocardial perfusion following administra-
tion of BMCePCs as determined by cardiac MRI, MuGA and 2D ECHO.
Compared to baseline, there was a signiﬁcant improvement in LVEF at
3 and 24 months in the treated patient. However, there was no
signiﬁcant improvement in scar size after administration of BMCePCs.
Nevertheless, this case study was designed to demonstrate the prelimi-
nary safety and effectiveness data for our rapid bedside point-of-care
technology (combination product) in the treatment of low ejection
fraction AMI.
The adult human body possesses the potential to repair damaged
cardiac tissue, and in the last decade considerable attempts have been
made to harness this intrinsic regenerative capability. Adult human
bonemarrow represents the richest source of multi-potency progenitor
cells. These progenitor cells can be harvested, processed/expanded and
applied to regenerative applications. Despite obtaining excellent results
in lab animal studies, human clinical results have remained under-
whelming in the prior studies. The review of current and past literature,
recent meta-analysis and reviews, all revealed critical stepwise proce-
dural, instrumentation, and chemical/biological variables that should
have been controlled and measured in order to ensure proper cardiac
repair and regeneration in everyday interventional cardiology settings.
Simply assuming speciﬁc cell types demonstrated in a lab model are
ready for clinical trial, and expectations that such biology alone is
predictable and reproducible equates to the pharmaceutical industry
completely skipping the quality demands and parameters of statistical
process control in manufacturing.
The main ﬁnding of the present study was that intracoronary cell
therapy after AMI was potentially safe and resulted in a modest yet sig-
niﬁcant increase in LVEF. LVEF is one of the key indications of mortality
rates post MI with a reduced LVEF being a risk factor for both sudden
and non-sudden death, with the odds ratio for 1-year mortality after
MI at 9.48 for patients with LVEF ≤30% compared with patients with
LVEF N50%, 2.94 for patients with LVEF 30–40%, whereas the risk was
not signiﬁcantly increased in patients with LVEF 40–50%. Intracoronary
cell therapy helps improve myocardial functions, however the exact
mechanism of action is still debatable. Several hypothesis have been pro-
posed and a recent well-conducted study suggested that bone marrow
derived progenitor cells do not transdifferentiate into cardiomyocytes,
instead they adopt mature hematopoietic characteristics.29,30 However,
adult CD34+ cells can differentiate into cardiomyocytes, mature
endothelial cells and smooth muscle cells in vivo.31 Another proposed
mechanism is that, following cell therapy angiogenesis increases, thus,
improving blood supply to the ischemic regions, which can potentially
aide in revascularization of hibernating myocardium32 and inhibit
cardiomyocyte apoptosis.33 The alternate possible reasons for LV recovery
Fig. 1. Images (A) and (C) show one section of the cardiacMR stacking used to calculate themyocardial volume at the 3- and 24-months exam post-BMCePC infusion, respectively. Images
(B) and (D) represent the LV transmurality index at 3- and 24-months post-BMCePC infusion, respectively.
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presentation of the patient.34
The regenerative potential of bonemarrowderived cellular products
is highly inﬂuenced by the handling, aspiration, processing, and
re-delivery techniques as well as the chemistry, biology and timing of
the cellular product intervention. It has been extensively reported and
is well understood that the chemokine receptor-4 (CXCR4)/stromal
cell-derived factor-1 (SDF-1) axis plays a crucial role in homing to and
engraftment of progenitor cells to the heart after myocardial infarction
(MI).15,16 Withinminutes following amyocardial infarction, the cardiac
tissue turns hypoxic leading to cardiacmyocytes apoptosis and upregu-
lation of several important factors, especially the stromal cell-derived
factor-1 (SDF-1) chemokine. The increased levels of SDF-1 lead to hom-
ing of endogenous and bone marrow derived progenitor cells including
endothelial progenitor cells (EPCs) that play a pivotal role in angiogen-
esis (formation of blood vessels). The progenitor cells that express
CXCR4 respond swiftly to an increased SDF-1 gradient. Although, pro-
genitor cells present in the bone marrow do express CXCR4 receptors,
they need tomobilize or egress into the blood stream to efﬁciently per-
form the cardiac repair. It has been suggested in prior publications that
bonemarrowpro-genitor cells becomemore responsive to SDF-1 over 4
to 7 days post MI, however, the local (heart organ) cardiac SDF-1 levels
decline quickly within 4 to 7 days from the cardiac injury (MI) leading
to ineffective prolonged homing of progenitor cells to the injured
tissue.17 Therefore, harvesting these potentially SDF-1 responsive,
CXCR4 expressing bone marrow stem/progenitor cells, and infusingTable 3
Time endpoints: left ventricular ejection fraction (LVEF) values and safety.
Measurement time Method Value MACE
Time 0 days 2D echo 35% N/A
Time 6 days MuGA b40% N/A
Time 7 days IC angiogram b40% None
Time 3 months F/U cMRI 55.30% None
Time 24 months F/U cMRI 60.30% Nonethem locally (proximally) to the stunted or scarred cardiac tissue repre-
sents a logical and viable approach for cardiac regenerative therapy.
Fig. 2 represents an overview of the approach.
The importance of the CXCR4/SDF-1 axis is unambiguous in the
arena of regenerative medicine, and chemicals that interfere with this
mechanism deﬁnitely impact the over-all efﬁcacy of the infused cellular
product. Anticoagulants, a chemical added to bone marrow aspirate to
prevent the formation of microthrombae, plays a crucial role in the
overall efﬁcacy of regenerative cell therapy. It is understood that the ad-
dition of any chemical entity in the presence of proteins or cells may
have an effect on their structure or function or both. Heparins are the
most commonly employed anticoagulants for bone marrow aspiration,
and are reported to disrupt the pivotal CXCR4/SDF-1 axis18 and
immunomodulation.19 Heparins have a high afﬁnity for SDF-1 (Kd
22.7 nM), and bind to SDF-1 by electrostatic interactions that can inhibit
its receptor (CXCR4) interactions.16 The heparin-treated bone marrow
cells become unresponsive due to inhibition of the CXCR4 receptor
internalization that further blocks CXCR4 downstream signaling.
It has also been reported that circulating VEGF levels, a potent
proangiogenic factor, decrease by 93.2 + 5% within 30 min of
unfractionated heparin (UFH) therapy.22 The decrease in circulating
VEGF levels could be due to sequestration of VEGF into the extracellular
matrix. Moreover, heparins are associated with high rates of pre-
procedural bleeding, which may be related to their inability to bind to
clot-bound thrombin. Heparins can bind to platelet factor-4 in vivo
that may lead to formation of antibodies against the heparin/PF-4
complex and can cause heparin induced thrombocytopenia (HIT).20
Williams et al. demonstrated that the presence of antibodies to the
platelet factor-4/heparin complex serves as an independent predictor
of myocardial infarction at 30 days in patients presenting with acute
coronary ischemic syndromes.21 Therefore, our ﬁrst variable control
that we have devised and utilized in the AMIRST procedure and combi-
nation product kit is a novel anticoagulation methodology utilizing a
U.S. FDA approved short synthetic peptide that can keep the aspirated
bonemarrow in a non-coagulated state, during processing and infusion,
without affecting the biological efﬁcacy of cellular product.
Fig. 2. Increase the responsiveness of CXCR4-positive bonemarrowprogenitor cells, however, due to limitedmobilization the effective repair does not take place. Harvesting, enriching and
infusing potential progenitor cells are our approach for cardiac repair and regeneration.
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derived cellular product is the processing technology employed to
harvest the desired cellular fraction(s). Some scientists and clinicians
suggest that different processing techniques utilized in bone marrow
processing, at least to some extent, are a plausible reason for conﬂicting
and unpredictable results in clinical trials.22 It has been reported in the
literature that efﬁcacy and functionality of bone marrow derived cellu-
lar product is signiﬁcantly inﬂuenced by various factors such as red
blood cell contamination,23 content of apoptotic cells, washing steps,
and inclusion of neutrophils. Till date, most clinical and pre-clinical
studies have used the Ficoll-paque density gradient method to extract
the cell fraction enriched with mononuclear cells, and most recently
the TIME randomized trial24 used such a combination of automation
and Ficoll-paque and reported consistently low total nucleated cell
recoveries. Manual cell preparation studies have reported that ﬁcoll-
paque methods result in a mere 15 to 30% recovery rates of bone mar-
row mononuclear cells following a multi-hour laboratory processing
requirement.25 The lower recovery rates of ﬁcoll-paque may among
others be a consequence of density-medium related cytotoxicity. More-
over, the manual ﬁcoll-paque method is highly user-dependent but
should have been addressed in the automated approach used in the
TIME study. This is likely another plausible reason for inconsistent re-
sults in clinical trials thus far.28We have thus focused on critical variable
number two by developing an automated chemical free “intelligent”
cell-processing technology with Thermogenesis Corporation (USA)
that yields reproducible cellular product and is independent of the
user, assuming basic training. The method produces autologousBMCePC, without the addition of density grademedium, at the patient's
bedside in under 30min. Additionally, a clinical team using the AMIRST
approach is able to verify that the harvesting and processing steps have
yielded the desired minimum cellular dose by employing our rapid
bedside diagnostics.
Handling time is a critical parameter in cellular therapy and the time
interval between bone marrow aspiration and delivery of cellular prod-
uct must be reduced. It has been suggested that bone marrow derived
autologous cellular products prevent adverse cardiac remodeling by a
synergy of mechanisms as described in Fig. 3. One of the crucial factors
essential for a remodeling minimization effect is the mobility of progen-
itor cells. Prerequisite for the success of cell therapy is the homing and,
thus, engraftment of transplanted cells into the target area. Themigrato-
ry capacity of the infused cells is amajor determinant of infarct remodel-
ing, disclosing a causal effect of progenitor cell therapy on regeneration
enhancement. Britten et al. ﬁrst time demonstrated that the migratory
capacity of transplanted progenitor cells is an independent predictor of
infarct remodeling as measured by MRI-determined LE volume.35 Simi-
larly Poole et al. showed that product potency (in terms of improvement
in perfusion and LVEF) was related to the mobility of CD34+ cells in an
SDF-1 gradient.26 Furthermore, they showed that cell mobility towards
the chemokine gradient declined over time following bonemarrow har-
vest, with amedian 57% decrease between 24 and 48 hours post-harvest
and a further 11% decline by 72 h. Thus, administration of cells without
delay after harvestmay reduce the quantity of cells required for the ther-
apeutic effect, increase the migratory capacity of the cells and enhance
the therapeutic effect of cell therapy.36,37 Thus, the numbers of CD34+
Fig. 3. Schematic representation of proposed mechanisms that stem/progenitor cells recruit for cardiac repair and regeneration following myocardial infarction (MI). Intra-coronary (IC)
delivery of stem/progenitor cells, upregulation of CXCR4 and egress of progenitor cells from the bone marrow into the vascular bed to sustain repair and modulate inﬂammation.
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factors that appear to determine potency of the cell therapy product. De-
livering the cellular product with a minimum interval lag time presents
an ideal technology to the enthusiastic clinicians. Our point-of-care
technology can accomplish the complete procedure, from bone marrow
harvest to infusion, in 60–90 min, thus minimizing any impact of time
and environmental effects on the therapeutic cells.
The ﬁnal critical variable controlled in our treatment method is
the utilization of an inherently cell friendly and endothelium safe
intracoronary catheter designed to measure and control the impact of
pressure, shear, and surface chemistry within the delivery lumen on
the therapeutic cells. Most studies analyze the cellular viability, and
fewer analyze the cellular potency of the cells pre- and post-traversing
the catheter. The lack of attention given in previous cardiac therapies
to the impact of such physical conditions has on the infuscate, again
opened the possibilities for highly unpredictable results. Our procedure
utilizes a proprietary controlled process and device which minimizes
and measures these critical variables.
Conclusion and future directions
In brief, we have developed a rapid bedside (point-of-care) method
and technology for the aspiration, processing and infusion of BMCePC,
as an adjuvant treatment in cardiovascular disorders – speciﬁcally
primary acute myocardial infarction. The methodology employs a
heparin-free bone marrow aspiration along with a user independent
automated processing system to extract BMCePC rapidly in a point-of-
care controlled environment. The technique helps overcomes few of
the current problems encountered in the ﬁeld of cardiac regenerative
medicine and provides the ﬁrst combination product (both device and
therapeutic cells) for a rapid point-of-care technology of aspirating,
isolating, and delivering of bone marrow derived progenitor cells and
factors from the patient's own body. Many experimental studies and
clinical trials have proven the feasibility, safety, and efﬁcacy of cell-based therapy, including our case study, however, the mechanisms
underlying the regeneration of damaged cardiac tissues by progenitor
cells are not fully understood. There are many issues related to the use
of cell therapy, including the eligibility of patients, optimal timing of
cell transfer, dosage, the best way to prepare the cells, method of cell
administration, and selection of the correct type of cells, that remain to
be solved. Thus, large scale randomized-controlled trials are warranted
to assess the clinical effects of the BMCePC administration in patients
with acute myocardial infarction with an optimal delivery systems.
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